Cadila Healthcare Q2 profit up 32.5%

MUMBAI: Cadila Healthcare Ltd reported a 32.5% year-on-year rise in consolidated net profit for the September-quarter, driven by strong US growth after it launched a generic of Lialda, an inflammatory bowel disease drug, with a six-month marketing exclusivity period. The company posted a consolidated net profit of ₹503.3 crore in the September quarter, against ₹379.9 crore a year ago. Sales increased 32.2% year-on-year to ₹3,154.9 crore.

COMPILED FROM MINT REPORTERS